Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study
Abstract Background The aims of the study were to evaluate potential differences among first-line treatment for EGFR mutant (m+) non-small cell lung cancer (NSCLC) patients with brain metastasis in China and to identify the factors influencing survival outcomes. Methods In this retrospective study,...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-023-10744-2 |
| _version_ | 1797853743174123520 |
|---|---|
| author | Huijuan Wang Ruyue Xing Mengmeng Li Mina Zhang Chunhua Wei Guowei Zhang Yuanyuan Niu Zhiyong Ma Xiangtao Yan |
| author_facet | Huijuan Wang Ruyue Xing Mengmeng Li Mina Zhang Chunhua Wei Guowei Zhang Yuanyuan Niu Zhiyong Ma Xiangtao Yan |
| author_sort | Huijuan Wang |
| collection | DOAJ |
| description | Abstract Background The aims of the study were to evaluate potential differences among first-line treatment for EGFR mutant (m+) non-small cell lung cancer (NSCLC) patients with brain metastasis in China and to identify the factors influencing survival outcomes. Methods In this retrospective study, 172 EGFRm + patients with advanced NSCLC who received a 1st generation EGFR tyrosine kinase inhibitor (TKI) were divided into 4 groups: A, EGFR-TKI (n = 84); B, EGFR-TKI + pemetrexed + cisplatin/carboplatin chemotherapy (CT) (n = 55); C, EGFR-TKI + bevacizumab (n = 15); and D, EGFR-TKI + pemetrexed + cisplatin/carboplatin CT + bevacizumab (n = 18). Intracranial and extracranial progression-free survival (PFS), the overall survival (OS), objective remission rates (ORRs) and adverse events were analyzed. Results Intracranial PFS of groups C + D was longer than for groups A + B (18.9 m vs. 11.0 m, P = 0.027). Extracranial PFS were longer in group B in comparison with group A (13.0 m vs. 11.5 m, P = 0.039) and in groups C + D compared to groups A + B (18.9 m vs. 11.9 m, P = 0.008). Median OS in groups A and B were 27.9 m and 24.4 m, respectively, while groups C and D have not yet achieved median OS. Significant difference was found in intracranial ORR between groups A + B vs. C + D (31.0% vs. 65.2%, P = 0.002). Most patients suffered grade 1–2 treatment-related adverse events, which were relieved soon after symptomatic treatment. Conclusions First-generation EGFR-TKI + bevacizumab treatment outperformed other regimens in EGFRm + NSCLC patients with brain metastasis. The therapy improved the control and delayed progression of intracranial lesions and prolonged survival times. |
| first_indexed | 2024-04-09T19:55:39Z |
| format | Article |
| id | doaj.art-c1094617e18b4e43ab968c0db112d0d4 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-09T19:55:39Z |
| publishDate | 2023-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-c1094617e18b4e43ab968c0db112d0d42023-04-03T05:30:37ZengBMCBMC Cancer1471-24072023-03-012311910.1186/s12885-023-10744-2Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective studyHuijuan Wang0Ruyue Xing1Mengmeng Li2Mina Zhang3Chunhua Wei4Guowei Zhang5Yuanyuan Niu6Zhiyong Ma7Xiangtao Yan8Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalAbstract Background The aims of the study were to evaluate potential differences among first-line treatment for EGFR mutant (m+) non-small cell lung cancer (NSCLC) patients with brain metastasis in China and to identify the factors influencing survival outcomes. Methods In this retrospective study, 172 EGFRm + patients with advanced NSCLC who received a 1st generation EGFR tyrosine kinase inhibitor (TKI) were divided into 4 groups: A, EGFR-TKI (n = 84); B, EGFR-TKI + pemetrexed + cisplatin/carboplatin chemotherapy (CT) (n = 55); C, EGFR-TKI + bevacizumab (n = 15); and D, EGFR-TKI + pemetrexed + cisplatin/carboplatin CT + bevacizumab (n = 18). Intracranial and extracranial progression-free survival (PFS), the overall survival (OS), objective remission rates (ORRs) and adverse events were analyzed. Results Intracranial PFS of groups C + D was longer than for groups A + B (18.9 m vs. 11.0 m, P = 0.027). Extracranial PFS were longer in group B in comparison with group A (13.0 m vs. 11.5 m, P = 0.039) and in groups C + D compared to groups A + B (18.9 m vs. 11.9 m, P = 0.008). Median OS in groups A and B were 27.9 m and 24.4 m, respectively, while groups C and D have not yet achieved median OS. Significant difference was found in intracranial ORR between groups A + B vs. C + D (31.0% vs. 65.2%, P = 0.002). Most patients suffered grade 1–2 treatment-related adverse events, which were relieved soon after symptomatic treatment. Conclusions First-generation EGFR-TKI + bevacizumab treatment outperformed other regimens in EGFRm + NSCLC patients with brain metastasis. The therapy improved the control and delayed progression of intracranial lesions and prolonged survival times.https://doi.org/10.1186/s12885-023-10744-2NSCLCTyrosine kinase inhibitorsBevacizumabBrain metastasisIntracranial metastasis |
| spellingShingle | Huijuan Wang Ruyue Xing Mengmeng Li Mina Zhang Chunhua Wei Guowei Zhang Yuanyuan Niu Zhiyong Ma Xiangtao Yan Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study BMC Cancer NSCLC Tyrosine kinase inhibitors Bevacizumab Brain metastasis Intracranial metastasis |
| title | Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study |
| title_full | Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study |
| title_fullStr | Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study |
| title_full_unstemmed | Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study |
| title_short | Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study |
| title_sort | clinical efficacy and prognosis analysis of treatment regimens for egfr mutant non small cell lung cancer and brain metastasis a retrospective study |
| topic | NSCLC Tyrosine kinase inhibitors Bevacizumab Brain metastasis Intracranial metastasis |
| url | https://doi.org/10.1186/s12885-023-10744-2 |
| work_keys_str_mv | AT huijuanwang clinicalefficacyandprognosisanalysisoftreatmentregimensforegfrmutantnonsmallcelllungcancerandbrainmetastasisaretrospectivestudy AT ruyuexing clinicalefficacyandprognosisanalysisoftreatmentregimensforegfrmutantnonsmallcelllungcancerandbrainmetastasisaretrospectivestudy AT mengmengli clinicalefficacyandprognosisanalysisoftreatmentregimensforegfrmutantnonsmallcelllungcancerandbrainmetastasisaretrospectivestudy AT minazhang clinicalefficacyandprognosisanalysisoftreatmentregimensforegfrmutantnonsmallcelllungcancerandbrainmetastasisaretrospectivestudy AT chunhuawei clinicalefficacyandprognosisanalysisoftreatmentregimensforegfrmutantnonsmallcelllungcancerandbrainmetastasisaretrospectivestudy AT guoweizhang clinicalefficacyandprognosisanalysisoftreatmentregimensforegfrmutantnonsmallcelllungcancerandbrainmetastasisaretrospectivestudy AT yuanyuanniu clinicalefficacyandprognosisanalysisoftreatmentregimensforegfrmutantnonsmallcelllungcancerandbrainmetastasisaretrospectivestudy AT zhiyongma clinicalefficacyandprognosisanalysisoftreatmentregimensforegfrmutantnonsmallcelllungcancerandbrainmetastasisaretrospectivestudy AT xiangtaoyan clinicalefficacyandprognosisanalysisoftreatmentregimensforegfrmutantnonsmallcelllungcancerandbrainmetastasisaretrospectivestudy |